Stock listing
Double Bond Pharmaceutical International Ab Class B
Selected listing: DBP.B · NGM · SEK · SE
Double Bond Pharmaceutical International Ab Class B (NGM:DBP.B), Health Technology. Latest release May 22, 2026: DBP.B: Q1 2026 delivered narrowed losses…
- Ticker
- NGM:DBP.B
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NGM
- Currency
- SEK
About Double Bond Pharmaceutical International Ab Class B
Double Bond Pharmaceutical International Ab Class B, trading under the ticker DBP.B, is a public company listed in Sweden. It focuses on pharmaceutical development and innovation within the industry.
Latest news from Double Bond Pharmaceutical International Ab Class B
DBP.B: Q1 2026 delivered narrowed losses and major clinical validation for Temodex
May 22, 2026
DBP.B: Equity restored and net loss reduced as SI-053 development progressed, but funding needs persist
February 26, 2026
DBP.B: Improved results and restored equity as S1053 advances toward potential partnerships
November 13, 2025
DBP.B: Revenue and net loss improved, with strong project progress and a major rights issue launched
August 25, 2025
DBP.B: Revenues rose and losses narrowed as SI053 clinical trial preparations were completed
May 22, 2025
All Double Bond Pharmaceutical International Ab Class B news →
Research Double Bond Pharmaceutical International Ab Class B
Double Bond Pharmaceutical International Ab Class B company profile
View the public company page for Double Bond Pharmaceutical International Ab Class B on 6ix.
Double Bond Pharmaceutical International Ab Class B news
Read company news and market updates connected to Double Bond Pharmaceutical International Ab Class B.
Double Bond Pharmaceutical International Ab Class B investor events
Find investor webinars, events, and replay context for Double Bond Pharmaceutical International Ab Class B.